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Available online xxxxLeber hereditary optic neuropathy (LHON) is an important cause of mitochondrial blindness among young
adults. In this study, we investigated the potential of four quinone analogues (CoQ1, CoQ10, decylubiquinone
and idebenone) in compensating for the deleterious effect of the m.11778GNA mitochondrial DNA mutation.
The LHONfibroblast cell lines tested exhibited reduced cell growth, impairedmitochondrial bioenergetics and el-
evated levels of reactive oxygen species (ROS). Idebenone increased ATP production and reduced ROS levels, but
the effect was partial and cell-specific. The remaining quinone analogues had variable effects and a negative im-
pact on certain mitochondrial parameters was observed in some cell lines.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Optic atrophy1. Introduction
Leber hereditary optic neuropathy (LHON) is a primary mitochon-
drial DNA (mtDNA) disorder characterised by bilateral sequential or si-
multaneous visual loss in young adults (Man et al., 2002). Affected
patients develop a dense central scotoma and visual acuity deteriorates
rapidly to 20/200 orworse. Three pointmutationswithin themitochon-
drial genome (m.3460GNA, m.11778GNA and m.14484TNC) account for
about 90% of all cases, with the m.11778GNA mutation being by far the
most prevalent (60–80%) cause of LHON worldwide (Newman andCCCP, carbonylcyanide-3
, coenzyme Q10; DCF, 2′,7′-
one; GAL, restrictive, galactose
db, idebenone; LHON, Leber
; MRS, magnetic resonance
oTracker Green; OCR, oxygen
on; PARP, poly (ADP-ribose)
tory control ratio; RFU, relative
oxygen species; SEM, standard
itochondrial Research, Institute
upon Tyne NE1 3BZ, United
Wai-Man).
. This is an open access article under
et al., Evaluating the therape
(2017), http://dx.doi.org/10.Biousse, 2004; Yu-Wai-Man et al., 2011). An abidingmystery of this dis-
order is why these mtDNA mutations have such a marked pathological
predilection for retinal ganglion cells (RGCs) and their projecting axons
within the optic nerve (Carelli et al., 2004). Spontaneous visual recovery
has been reported in up to 25% of patients affected with LHON and the
milderm.14484TNCmutation carries a relatively better visual prognosis
(Newman and Biousse, 2004; Yu-Wai-Man et al., 2011). However, visu-
al recovery is invariably incomplete and the majority of affected LHON
carriers will remain severely visually impaired and classified as legally
blind. The peak age of onset is in the second and third decades of life
and the sudden onset of mostly irreversible visual loss in otherwise
healthy young individuals has major socioeconomic consequences
(Kirkman et al., 2009a). Treatment options for LHON remain limited
and management is largely supportive, which is a frustrating situation
for patients and their families, and the clinicians overseeing their care.
LHON has an estimated prevalence of 1 in 30,000 and there are con-
siderable challenges, both practical and financial, in conducting ade-
quately powered randomised controlled trials, which remain the gold
standard for establishing the therapeutic efficacy and safety of a pro-
posed intervention (Gorman et al., 2015; Man et al., 2003). Varying
combinations of high-dose vitamins and supplementswith putativemi-
tochondrial antioxidant properties have been given to patients with
LHON in the hope of improving the visual prognosis, but none of these
drug cocktails are properly evidence-based (Pfeffer et al., 2013;the CC BY license (http://creativecommons.org/licenses/by/4.0/).
utic potential of idebenone and related quinone analogues in Leber
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Table 1
Clinical details of affected LHON carriers.
Patient Onset (Yrs)a Smokerb Visual recoveryc Visual acuityd
RE LE
LHON-A 21 No No HM CF
LHON-B 18 No Yes 20/30 CF
LHON-C 45 Yes No CF CF
LHON-D 18 No No HM HM
CF = counting fingers; HM = hand movements; LE = left eye; RE = right eye; Yrs =
years.
a Age of onset of visual loss.
b Smoking status prior to disease onset.
c Spontaneous visual recovery with none of the patients having been treated with
quinone analogues following disease onset.
d Best-corrected visual acuity at the last clinic visit, which was at a similar level at the
nadir except for the right eye of patient LHON-B.
2 P. Yu-Wai-Man et al. / Mitochondrion xxx (2017) xxx–xxxYu-Wai-Man et al., 2014). A promising class of compounds for LHON is
the ubiquinone family ofmolecules, in particular idebenone.Most of the
mtDNA mutations that are known to cause LHON affect complex I sub-
units and as a result, there is impaired transfer of high-energy electrons
to complex III, which is an essential step in mitochondrial oxidative
phosphorylation (OXPHOS) (Carelli et al., 2004). The structural and
functional defect of complex I triggers a downstream cascade of events,
which ultimately compromises RGCs and precipitate progressive optic
nerve neurodegeneration. There is ongoing debate whether the bioen-
ergetic deficit in LHON directly commits RGC to cell death or whether
it is driven primarily by increased reactive oxygen species, or possibly
both having a synergistic deleterious impact (Carelli et al., 2004;
Levin, 2015; Yu-Wai-Man et al., 2011). Irrespective of this unresolved
point of contention, an attractive dual strategy would be to improve
electron transfer along themitochondrial respiratory chain tomaximise
OXPHOS and ATP production, whilst minimising in parallel ROS levels.
Coenzyme Q10 (CoQ10) is natural lipid-soluble quinone analogue
and as a result of its intrinsic hydrophobic properties, it freely circulates
within the mitochondrial inner membrane (Hargreaves, 2014). The
molecule contains a redox active benzoquinone ring that is conjugated
to an isoprenoid side chain consisting of 10 isoprenyl units, with the ac-
tual number of these units forming the basis of the biochemical nomen-
clature. In its reduced form, CoQ10 is the predominant electron carrier of
the mitochondrial respiratory chain and it mediates the efficient shut-
tling of electrons from complexes I and II, and other flavoprotein dehy-
drogenases, to complex III. As a result, oral supplementation of CoQ10
has been used for a broad range of mitochondrial OXPHOS diseases,
but with the exception of patients with primary CoQ10 deficiency,
there is no convincing evidence of any clear benefit (Hargreaves,
2014). A major limitation of CoQ10 is its inability to cross the blood-
brain barrier and to rectify this biophysical constraint, newer-genera-
tion quinone analogues have been developed to increase the bioavail-
ability of the active moiety and potentially maximise its therapeutic
potential. One such compound is idebenone (2,3-dimethoxy-5-meth-
yl-6-(10-hydroxydecyl)-1,4-benzoquinone), which has a shorter side
chain and is a hydrosoluble molecule compared with CoQ10 (Imada et
al., 1989; Nagai et al., 1989). Idebenone has shown promise as a treat-
ment modality for patients with visual loss secondary to LHON, but
only a subgroup of patients with the m.11778GNA mutation seems to
benefit, and there is still uncertainty about the magnitude of the visual
benefit when compared with the natural history of the disease (Carelli
et al., 2011; Klopstock et al., 2013; Klopstock et al., 2011; Newman,
2011).
In order to obtain pre-clinical data and support the case for early-
phase clinical trials, we have optimised an in vitro functional test
panel to investigate the effects of candidate drug molecules on key as-
pects of mitochondrial functionwith the use of patient-derived primary
fibroblasts (Golubitzky et al., 2011; Soiferman et al., 2014). As reported
previously for patients with nuclear-encoded complex I respiratory
chain disorders, such an experimental approach can provide not only
new insights into disease mechanisms, but it is also an attractive, cost-
effective approach for targeted drug screening. In this study, we have
made use of primary fibroblast cell lines carrying the m.11778GNAmu-
tation to firstly explore the pathological consequences of this mtDNA
mutation on mitochondrial function and cell survival, and secondly, to
investigate whether supplementation with various quinone analogues
could potentially rescue (or alternatively exacerbate) the observed dis-
ease phenotype.
2. Materials and methods
2.1. Patients and fibroblast cell lines
Primary fibroblast cell cultures (LHON A-D) were established from
skin biopsies obtained from four unrelated white Caucasian affected
male LHON carriers harbouring the m.11778ANG mutation atPlease cite this article as: Yu-Wai-Man, P., et al., Evaluating the therape
hereditary optic neuropathy, Mitochondrion (2017), http://dx.doi.org/10.homoplasmic levels (Table 1). All four patients presented with a classi-
cal pattern of visual loss characterised by bilateral sequential optic neu-
ropathy and rapid painless visual deterioration to counting fingers (CF)
or worse. None of them were treated with CoQ10, idebenone or other
quinone analogues after a confirmed molecular diagnosis had been
made and prior to a skin biopsy being taken. One patient (LHON-B) ex-
perienced a significant amount of visual recovery that was, however,
limited to his right eye. Visual acuity in that eye improved from CF at
the nadir to 20/30 about one year after first disease onset and in the ab-
sence of any specific treatment. All the skin biopsies were taken after
the onset of visual loss with the patient's informed consent. This study
had the relevant institutional approval and it complied with the Decla-
ration of Helsinki.
2.2. Materials
Aliquots of coenzyme Q1 (CoQ1), coenzyme Q10 (CoQ10),
decylubiquinone (DQ, Sigma-Aldrich, Rehovot, Israel), and idebenone
(Idb, Santhera Pharmaceuticals, Liestal, Switzerland) were kept frozen
as 10mMstock solutions in DMSO.MTG (Molecular Probes, Eugene, Or-
egon, USA), TMRE and DCF (Biotium, Harvard, CA, USA) were diluted
and stored according to the manufacturer's instructions. Unless other-
wise stated, reagents were obtained from Sigma-Aldrich (Rehovot,
Israel).
2.3. Tissue culture and experimental conditions
Fibroblasts weremaintained in permissive DMEM (Biological Indus-
tries, Kibbutz Beit Haemek, Israel) medium containing 4.5 g glucose
(GLU) per liter and supplemented with 10% fetal calf serum, 50 μg/ml
uridine, and 110 μg/ml pyruvate at 37 °C under 5% CO2 conditions.
Cells were seeded in triplicates at a concentration of 4 × 103 cells/
100 μl on four identical 96 well microtiter plates. The following day,
the mediumwas removed and the wells were washed once with phos-
phate buffered saline (PBS) before the addition of fresh DMEM (GLU)
medium or a restrictive glucose-free DMEM medium to prevent ATP
production from glycolysis (Biological Industries, Kibbutz Beit Haemek,
Israel) supplemented with 10% dialyzed fetal calf serum and 5 mM
galactose (GAL). Quinone analogues at a final concentration of 1 μM
were added to the growth medium as previously described
(Golubitzky et al., 2011; Soiferman et al., 2014). Cell growth and mito-
chondrial function were assessed after a 72-hour incubation period.
2.4. Assessment of cell growth
Cell growthwas assessed bymeasuring cellular contentwith a color-
imetric method based on methylene blue (MB) staining of basophilic
cellular components, which is independent of redox status (Pelletier
et al., 1988). Cells in themicrotiterwellswere fixedwith glutaraldehydeutic potential of idebenone and related quinone analogues in Leber
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The absorbance of the extracted dye was measured at 620 nm (A620).
2.5. Intracellular ROS production
The growth medium was removed and replaced with 10 μM 2′,7′-
dichlorodihydrofluorescein diacetate (DCF) in phosphate buffered sa-
line with magnesium and calcium (PBS-MgCa) for 20 min at 37 °C
under 5% CO2 conditions. DCF was replaced with 100 ml fresh PBS-
MgCa, incubated at 30 °C for 20 min and fluorescence was measured
subsequently with λex 485 nm and λem 520 nm. ROS production was
calculated as relative fluorescence units (RFU) normalized to cellular
growth A620.
2.6. Cellular ATP content and mitochondrial ATP synthesis
Cellular ATP content was measured using the ATPlite (Perkin Elmer,
Waltham, MA, USA) luminescence assay kit according to the
manufacturer's instructions. For mitochondrial ATP synthesis, we
adapted an assay that we have previously described in lymphocytes
using microtiter plates (Negari et al., 2013). Briefly, cells were rinsed
in PBS and incubated for 20min at 37 °C in 50 μl assay buffer containing
150 mM KCl, 10 mM potassium phosphate buffer (pH 7.4), 25 mM Tris
(pH 7.4), 2 mM EDTA, 0.025% fatty-acid-free bovine serum albumin
(BSA), 40 μg/ml digitonin, 5 mM glutamate, and 1mMmalate. ATP con-
tent was calculated as relative luminescence (RLU) normalized to cellu-
lar growth A620.
2.7. Mitochondrial content and membrane potential
Cells grown in microtiter plates were incubated with 200 nM
MitoTracker Green (MTG) in growth medium for 45 min at 37 °C
under 5% CO2 conditions before the addition of 50 nM
tetramethylrhodamine ethyl ester (TMRE) for an additional 45 min.
The medium was removed and after being rinsed, the cells were re-
placed in PBS. Fluorescence was measured at 37 °C with λex 485 nm
andλem 528 nm forMTG, andλex 485nmandλem590 nm for TMRE.Mi-
tochondrial content was calculated as MTG RFU normalized to cell
growth A620. Mitochondrial membrane potential (Δψm) was derived
from the relative fluorescence ratio of TMRE to MTG (TMRE-RFU/
MTG-RFU). All luminescence, fluorescence and absorbance measure-
ments inmicrotiterwellswere performedwith a SynergyHTmicroplate
reader (Bio-Tek instruments, Vinoosky VT, USA).
2.8. Oxygen consumption
Oxygen consumption rate (OCR)wasmeasured using anXF24 extra-
cellularflux analyzer (Seahorse Biosciences, North Billeric,MA, USA). Fi-
broblasts were seeded 20,000 cells/well on an XF24-well plate in 0.3 ml
GLU medium. The following day cells were rinsed once with PBS and
medium was replaced with 0.5 ml fresh GLU, with or without quinone
analogues at a final concentration of 1 μM. After 72 h, the growthmedi-
um was changed to a medium with the same composition as GLU, but
with unbuffered DMEM (Seahorse Biosciences, North Billeric, MA,
USA) and the plate was equilibrated at 37 °C for 1 h before themeasure-
ments. After 10 min of basal OCR measurements, carbonylcyanide-3
chlorophenylhydrazone (CCCP) was injected to reach a final concentra-
tion of 5 μM and themaximal OCRwasmeasured. Background OCRwas
measured after injection of rotenone and antimycin to afinal concentra-
tion of 3 μM each. OCR was normalized to cellular growth. Respiratory
control ratio (RCR) was estimated as maximal/basal OCR ratio.
2.9. Apoptosis assays
Apoptosis was assessed by western blot analysis of two markers,
caspase 3 and poly (ADP-ribose) polymerase (PARP). Cells treatedPlease cite this article as: Yu-Wai-Man, P., et al., Evaluating the therape
hereditary optic neuropathy, Mitochondrion (2017), http://dx.doi.org/10.with staurosporine (Merck Millipore) were included as a positive con-
trol group. Total protein concentration was determined with the Brad-
ford assay. Cell lysates containing 30 μg of protein were loaded onto
pre-cast NuPAGE 4–12% Bis-Tris gels (Life Technologies) and electro-
phoresis was carried out at 200 V in NuPage MES running Buffer (Life
Technologies). Gels were transferred to PVDF membranes using iBlot
Gel Transfer Stacks (Life Technologies) and membranes were probed
with anti-caspase 3 (1 in 500, Cell Signaling, #9662), anti-PARP (1 in
500, Cell Signaling, #9542), and anti-β tubulin (1 in 2000, Abcam,
#15568) antibodies. Following incubation with horseradish peroxi-
dase-conjugated secondary antibodies (1 in 2000, Dako, P0399), signals
were visualised with Clarity Western ECL substrate (Bio-Rad) and the
Biospectrum500 Imaging System (UVP). The results obtainedwere nor-
malized to β tubulin.
For the TUNEL assay, cells were grown in 96-wellmicrotiter plates in
restrictive galactose medium for 72 h. Apoptosis was assessed by a
quantitative colorimetric assay using the HT TiterTACS assay kit
(Trevigen, Gaithersburg, MD, USA) as per the manufacturer's protocol.
2.10. Statistical analysis
Thedata are shown as themean± standard error of themean (SEM)
of triplicate independent experiments. Groups were compared using
the Student's t-test with the IBM-SPSS™ v.20 software (IBM Corp.
Armonk, NY) and a P value b 0.05 was considered as statistically
significant.
3. Results
3.1. LHON fibroblasts exhibit decreased cell growth
Cell growth was reduced in the LHON cell lines compared with con-
trols in permissive glucose-containing media and this effect was signif-
icant for LHON-B and LHON-D (Fig. 1). The impairment in cell growth
caused by them.11778GNAmutationwas further accentuated in restric-
tive galactose media, with all four LHON cell lines showing a marked
and significant decrease compared with glucose media. There was a
trend towards improved cell growth with CoQ10, decylubiquinone and
idebenone in most cells, which was significant for controls and LHON-
D under glucose, but not galactose media conditions. Paradoxically,
CoQ1 had a significant detrimental effect on cell growth when added
to three of the four LHON cell lines (LHON-A, LHON-C and LHON-D).
3.2. ROS production is increased in LHON fibroblasts
All four LHON cell lines demonstrated significantly elevated ROS
levels comparedwith controls, especially LHON-A (Fig. 2). Amarked re-
duction in ROS levels was observed for LHON-A and LHON-C with all
four quinone analogues tested. Decylubiquinone was the most effective
agent with ROS production decreasing to control levels or lower in all
four LHON cell lines. LHON-B and LHON-D did not show a positive re-
sponse to CoQ1 and idebenone, and therewas a trend towards increased
ROS levels in LHON-B with CoQ10 supplementation, which was not sta-
tistically significant.
3.3. Mitochondrial bioenergetics is impaired by the m.11778GNA mtDNA
mutation
Mitochondrial membrane potential was not adversely affected by
the m.11778GNA mutation or influenced by the quinone additives, ex-
cept for LHON-Cwhere a relative decrease comparedwith theuntreated
values for this cell line was observed with CoQ1 (Supplementary Fig. 1).
Although cellular ATP content was not compromised (data not shown),
mitochondrial ATP synthesis was markedly reduced in all four LHON
cell lines. No significant improvement in mitochondrial ATP synthesisutic potential of idebenone and related quinone analogues in Leber
1016/j.mito.2017.01.004
Fig. 1. Effect of culture media and quinone analogues on cell growth. Cells were grown either in permissive glucose-containing medium (GLU) or in restrictive galactose (GAL) medium.
Cells were also supplemented with 1 μM quinone analogues; coenzyme Q1 (CoQ1), coenzyme Q10 (CoQ10), decylubiquinone (DQ) or idebenone (Idb). Cell growth was measured by
methylene blue (MB A620) in either GLU or GAL medium. The results are presented as the mean ± SEM (#P b 0.05 effect of m.11778GNA compared with controls (n= 5) in the same
medium; *P b 0.05 effect of additive).
4 P. Yu-Wai-Man et al. / Mitochondrion xxx (2017) xxx–xxxwas observed on supplementation with quinone analogues, except for
the LHON-D cell line when treated with idebenone (Fig. 3).
Maximal OCRwas decreased for all four LHON cell lines and this was
particularly pronounced for LHON-A and LHON-C (Fig. 4A). A partial de-
crease in RCR, which is a marker of mitochondrial uncoupling, was also
observed (Fig. 4B). Idebenone had a significant positive effect on maxi-
mal OCR in LHON-A and LHON-C with RCR remaining unchanged. The
remaining quinone analogues demonstrated variable effects. Interest-
ingly, CoQ1 and decylubiquinone decreased maximal OCR in LHON-D
without significantly affecting RCR.3.4. No evidence of apoptosis in LHON fibroblasts
Western blot analysis of cleaved caspase-3 and PARP showed no sig-
nificant difference between all four LHON cell lines when compared
with controls (Supplementary Fig. 2). Similarly, there was no evidence
of increased apoptosis with the TUNEL assay under galactose media
conditions (data not shown).Fig. 2. Effect of quinone analogues on ROS production. Cells were grown in glucose-
containing medium (GLU) only or in the presence of 1 μM quinone analogues;
coenzyme Q1 (CoQ1), coenzyme Q10 (CoQ10), decylubiquinone (DQ) or idebenone
(Idb). The level of ROS production was assayed by DCF. The fluorescence (DCF-RFU) was
normalized to cell growth (MB A620) and the results are presented as the mean ± SEM
(#P b 0.05 effect of m.11778GNA compared with controls (n = 5); *P b 0.05 effect of
additive).
Please cite this article as: Yu-Wai-Man, P., et al., Evaluating the therape
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The m.11778GNA mutation accounts for the majority of LHON cases
worldwide and it affects a key complex I subunit of the mitochondrial
respiratory chain (Newman and Biousse, 2004; Yu-Wai-Man et al.,
2011). There is currently some debate in the literature on the patho-
physiological mechanisms that link mtDNA LHON mutations with RGC
loss. Previous work on LHON cybrids and a variety of patient-derived
tissues, including blood and skeletal muscle, indicate impairment inmi-
tochondrial biogenesis with reduced complex I-driven ATP synthesis
(Carelli et al., 2004; Yu-Wai-Man et al., 2011). This observation has
been further substantiated in vivo with 31P–MRS (magnetic resonance
spectroscopy) and the m.11778GNA mutation was associated with the
most pronounced reduction in mitochondrial ATP synthesis, followed
by the m.14484TNC, and m.3460GNA mutation (Lodi et al., 1997). Be-
sides the impact of LHON mutations on OXPHOS, there is increasing
awareness of the potential primary role of increased ROS levels in trig-
gering RGC loss (Levin, 2015). A mouse model has been created with a
homoplasmic m.13997GNA mutation withinMTND6, which causes an
amino acid substitution (p.Pro25Leu) similar to them.14600GNAmuta-
tion previously reported in a family with Leigh syndrome and opticFig. 3. Mitochondrial ATP production. Cells were grown in glucose-containing medium
only (GLU) or in the presence of 1 μM quinone analogues; coenzyme Q1 (CoQ1),
coenzyme Q10 (CoQ10), decylubiquinone (DQ) or idebenone (Idb). Mitochondrial ATP
content was measured after digitonin treatment and incubation with glutamate and
malate. The relative luminescence (RLU) was normalized to cell growth (MB A620) and
the results are presented as the mean ± SEM (#P b 0.05 effect of m.11778GNA
compared with controls (n= 5); *P b 0.05 effect of additive).
utic potential of idebenone and related quinone analogues in Leber
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Fig. 4. Mitochondrial respiration under basal and maximal conditions. Oxygen
consumption was measured in cells grown in glucose-containing medium only (GLU) or
in the presence of 1 μM quinone analogues; coenzyme Q1 (CoQ1), coenzyme Q10
(CoQ10), decylubiquinone (DQ) or idebenone (Idb). [A] Maximal oxygen consumption
rate (MAX OCR) after the addition of an uncoupler CCCP and normalized to cell growth
(MB A620). [B] Respiratory control ratio (RCR) calculated as the ratio between MAX
OCR and the basal oxygen consumption rate. The results are presented as the mean ±
SEM (*P b 0.05 effect of m.11778GNA compared with controls (n = 5); ∧P b 0.05 effect
of additive).
5P. Yu-Wai-Man et al. / Mitochondrion xxx (2017) xxx–xxxatrophy (Malfatti et al., 2007). The mutant mice developed some of the
key histopathological features seen in the optic nerves of affected LHON
patients, namely, neuronal accumulation of abnormal mitochondria,
swelling of RGC axons and demyelination (Lin et al., 2012). Interesting-
ly, mitochondrial analysis showed decreased complex I activity and in-
creased ROS production, but no diminution of ATP production was
detected.
Our data obtained from patient-derived fibroblasts harbouring the
m.11778GNA mutation suggest that both impaired mitochondrial bio-
energetics and elevated cellular ROS levels could contribute to RGC
loss in LHON, perhaps in a synergistic fashion as both factors are intrin-
sically related. Strikingly, cell growth was markedly impaired in all four
LHON cell lines especiallywhen theywere deprived of glucose under re-
strictive galactose media conditions, thereby forcing them to rely solely
on mitochondrial OXPHOS as their energy source. Accordingly, mito-
chondrial ATP productionwas also markedly decreased whilst ROS pro-
duction was elevated. Although we did not find evidence of increased
apoptosis, this might simply reflect the limitation of the cell type that
was used in our experiments. More plausibly, RGCs carrying a patholog-
ical LHONmutation operate under a precarious environmentwithin the
inner retina, dominated by chronic mitochondrial dysfunction, until a
tipping point is reached that precipitates disease conversion in at-risk
LHON carriers. These more dynamic situations in a complex neuronal
structure like RGCs are clearly not reproducible in a simpler in vitroPlease cite this article as: Yu-Wai-Man, P., et al., Evaluating the therape
hereditary optic neuropathy, Mitochondrion (2017), http://dx.doi.org/10.fibroblast model. In keeping with the need for a secondary trigger, re-
cent studies have reinforced the role of smoking and a reduction in cir-
culating oestrogen levels as risk factors for disease conversion in LHON
(Giordano et al., 2011; Giordano et al., 2015; Kirkman et al., 2009b).
Spontaneous visual recovery in LHON, when it does occur, is incom-
plete and the majority of patients remain chronically visually disabled
(Kirkman et al., 2009a). Treatment options for this mitochondrial disor-
der are still limited, but pharmacological options aimed at improving
mitochondrial OXPHOS and reducing ROS levels are offering renewed
hope to patients and their families. There are several limitations to the
use of CoQ10 in LHON, in particular its inability to cross the blood-
brain barrier in order to reach sufficiently high levels within the RGC
layer (Giorgio et al., 2012; Gueyen et al., 2015; Hargreaves, 2014).
Idebenone is a newer-generation quinone analogue that circumvents
this therapeutic barrier and based on anecdotal LHON case reports,
this compound seemed to have a degree of visual benefit for some pa-
tients, but not all (Barnils et al., 2007; Haefeli et al., 2011; Heitz et al.,
2012; Mashima et al., 2000). Those initial observations led to the
RHODOS (Rescue of Hereditary Optic Disease Outpatient Study,
ClinicalTrials.gov identifier: NCT00747487) trial, which was a
multicentre, double-blind, randomised treatment study comparing
idebenone, at a dose of 300 mg three times per day, with placebo
(Klopstock et al., 2011). A total of 85 patients with a confirmed
mtDNA mutation (m.3460GNA, m.11778GNA, and m.14484TNC) and
with disease duration of up to five years were recruited. The RHODOS
trial failed to show a benefit for its pre-specified primary end point
(best recovery of visual acuity at week 24), but all of the secondary
end points showed a positive trend towards visual improvement in
the idebenone-treated group (Klopstock et al., 2011). A retrospective
Italian study of 103 patients subsequently indicated that patients
receiving idebenone were more likely to recover vision if treatment
was initiated early and if it was maintained for longer than the 24-
week regimen used in the RHODOS trial (Carelli et al., 2011). A market-
ing authorisation application by Santhera Pharmaceuticals Ltd. (Liestal,
Switzerland) to the European Medicines Agency's Committee for
Medicinal Products for Human Use (CHMP) was initially rejected, but
based on additional data collected as part of a named-patient access
programme, idebenone has recently been approved under exceptional
circumstances for the treatment of visual impairment in patients affect-
ed with LHON (http://www.ema.europa.eu/ema/index.jsp?curl=
pages/medicines/human/medicines/003834/smops/Positive/human_
smop_000835.jsp&mid=WC0b01ac058001d127, accessed on 28 De-
cember 2016). Overall, the current body of evidence does support a vi-
sual benefit with idebenone in acute LHON, but only in a subgroup of
treated patients and importantly, it is not possible to predict who will
respond. Furthermore, it should be stressed that there is no solid evi-
dence base to guide the optimal dose and duration of treatment, and it
remains debatable whether idebenone has any beneficial effect once
optic atrophy has become established in the chronic phase of the
disease.
Our study on LHON fibroblasts confirms that idebenone can have a
positive effect on OXPHOS by promoting the efficiency of electron flux
along the mitochondrial respiratory chain. This effect was associated
in two cell lines (LHON-A and LHON-C) with a consequent reduction
in ROS production and in one cell line (LHON-D) with improved ATP
production. Importantly, the response to quinone supplementation
was cell-specific and the detrimental effects of the m.11778GNA muta-
tion on mitochondrial function were not fully compensated. The partial
response with idebenone supplementation and the observed variability
between the LHON cell lines essentially mirrors the clinical experience
of treating patients with idebenone (Carelli et al., 2011; Klopstock et
al., 2013; Klopstock et al., 2011; Newman, 2011). A note of caution on
the use of certain quinone analogues for patients with LHON, and by ex-
tension other mitochondrial diseases, is also warranted. It is well
established that drugs can have marked inter-individual responses
and the assumption of safety for a particular class of molecules doesutic potential of idebenone and related quinone analogues in Leber
1016/j.mito.2017.01.004
6 P. Yu-Wai-Man et al. / Mitochondrion xxx (2017) xxx–xxxnot preclude idiosyncratic adverse effects. In the LHON cell lines used in
our study, certainmitochondrial parameters were adversely affected by
CoQ1, CoQ10 and decylubiquinone, with the detrimental effect being
more pronounced with CoQ1. Although, we did not observe a general-
ised detrimental response with any of these compounds, and with the
added caveat that we only tested four LHON cell lines, all of which car-
ried the m.11778GNA mutation, these findings do highlight the central
concept of primum non nocere in medical practice. CoQ1 has been
found to impair astrocyte function, possibly through the depletion of
NAD(P)H (Dragan et al., 2006). Although idebenone did not have any
negative effects on the cells and parameters used in our study, rather
surprisingly, idebenone had an adverse impact on RGC dendrite mor-
phology and visual function when fed to wild-type mice (Smith et al.,
2016). We still have an incomplete understanding of the pathophysiol-
ogy of LHON and the variable modes of action of different quinone ana-
logues, including idebenone, clearly substantiate the conservative
approach adopted by most experts not to recommend their prophylac-
tic use for asymptomatic LHON carriers. The therapeutic benefit of other
shorter-chain quinone analogues such as alpha-tocotrienol quinone
(EPI-743), which can cross the blood brain barrier, also need to be inves-
tigated further (Shrader et al., 2011).
5. Conclusions
Consistent with recently published clinical studies, our in vitro fibro-
blast data indicate a patient-specific response to idebenone and this
specific quinone analogue is not able to fully reverse the deleterious
consequences of the m.11778GNA mutation on mitochondrial function.
Furtherwork is urgently needed to develop better treatment options for
this devastating cause of mitochondrial blindness among young adults.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.mito.2017.01.004.
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